Latest Gabather News & Updates
See the latest news and media coverage for Gabather. We track all announcements, press releases, and industry mentions in real time, all in one place.
Pharmaceutical company developing CNS therapeutics
gabather.com- Headquarters
- Södertälje, Sweden
- Founded year
- 2014
- Company type
- Public company
- Number of employees
- 4–10
Latest news about Gabather
Company announcements
-
Gabather announces GT-002 study results
Presents acute effects on psychophysiological and cognitive measures. Dated 25 November 2025. Download presentation available.
-
Gabather begins GT002 capsule production
CEO announces milestone at partner facility in Spain for upcoming clinical trial. Capsules finalize this week, followed by packaging, labeling, and shipment to Denmark.
-
Gabather releases GT-002 EEG-fMRI study initial findings
The findings are available for download via presentation. Date: 21 January 2025.
-
Gabather summarizes progress over five years
The company describes clinical progress for GT-002, preclinical studies, EEG results, phase I/II studies and collaborations with CNSR and Karolinska Institutet.
Media coverage
-
Gabather carries out a directed new share issue of SEK 4,2 million - Biostock
Gabather is conducting a directed new share issue of approximately SEK 4,2 million with the aim of strengthening the balance sheet and current working capital...
-
Gabather Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct a Clinical Phase II Study with GT-002
STOCKHOLM, April 10, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) announces that the Company has signed a Collaborative Agreement with the...
-
Gabather reports initial positive results from the EEG/fMRI target engagement study
STOCKHOLM, March 7, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports initial positive results from the EEG/fMRI target engagement study...
-
Gabather files two new patent applications to secure novel findings on the effects of GT-002 for the treatment of psychiatric disorders
STOCKHOLM, March 18, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports that two new US provisional patent applications based on...
Track Gabather and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Gabather competitors & trending companies
Browse news for competitors to Gabather and other trending companies.
Asarina Pharma
AlzeCure Pharma
Sironax
Aperture Therapeutics
Attentive
Klaviyo
Twilio
Insider One
Zeta Global
Iterable
Braze
Optimove
Bluecore
BlueConic
Amperity
Wero
BLIK
EPI
Swish
Affirm
Brite Payments
TCS
Overview Energy
Adfin
Ineffable Intelligence
Mechanize
Hexatronic
Alimak Group
Lindab Group
NYAB
Noon Energy
Nordan AI
Mips
Vexlum